| 41.84 0.76 (1.85%) | 10-29 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 52.47 |
1-year : | 61.29 |
| Resists | First : | 44.93 |
Second : | 52.47 |
| Pivot price | 40.98  |
|||
| Supports | First : | 40.36 |
Second : | 37.54 |
| MAs | MA(5) : | 41.06 |
MA(20) : | 41.39 |
| MA(100) : | 44.62 |
MA(250) : | 47.49 |
|
| MACD | MACD : | -0.5 |
Signal : | -0.7 |
| %K %D | K(14,3) : | 60.9 |
D(3) : | 58.1 |
| RSI | RSI(14): 50.5 |
|||
| 52-week | High : | 59.68 | Low : | 37.54 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ SUPN ] has closed below upper band by 32.8%. Bollinger Bands are 2.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 44.24 - 44.4 | 44.4 - 44.54 |
| Low: | 40.34 - 40.53 | 40.53 - 40.7 |
| Close: | 41.54 - 41.8 | 41.8 - 42.05 |
Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for central nervous system (CNS) disorders within the United States. Its portfolio of marketed products includes Trokendi XR, an extended-release topiramate formulation prescribed for both epilepsy management and migraine prevention. Another key product is Oxtellar XR, an extended-release oxcarbazepine designed for the standalone treatment of partial-onset epileptic seizures in patients aged 6 to 17 and adults. The company also offers Qelbree, a selective norepinephrine reuptake inhibitor approved for attention-deficit hyperactivity disorder (ADHD) in children and adolescents aged 6 to 17. For advanced Parkinson's Disease (PD) patients, APOKYN offers acute, intermittent relief during "off" episodes of hypomobility, and XADAGO serves as an adjunctive treatment with levodopa/carbidopa for those experiencing similar off periods. Other offerings include GOCOVRI, which targets dyskinesia in PD patients, and Osmolex ER, used for Parkinson's disease and drug-induced extrapyramidal reactions in adults. MYOBLOC, a Type B toxin, is indicated for cervical dystonia and sialorrhea in adults. Beyond its commercial portfolio, Supernus is actively developing several investigational therapies. These include Qelbree (SPN-812), which has successfully completed Phase III trials for ADHD. SPN-830, a late-stage drug/device combination, aims to prevent off episodes in PD patients. SPN-817 is a novel compound in Phase I trials for severe epilepsy. SPN-820 is undergoing Phase II trials for resistant depression, and SPN-443 and SPN-446 are in earlier, preclinical stages for various CNS indications. Products are distributed through a network of pharmaceutical wholesalers, specialty pharmacies, and authorized distributors. Established in 2005, Supernus Pharmaceuticals is headquartered in Rockville, Maryland.
Thu, 29 Oct 2026
SUPN: Record Q3 revenue and strong growth products lifted standalone FY2026 guidance - TradingView
Thu, 29 Oct 2026
Supernus Pharmaceuticals Q3 2026 Earnings Call Transcript - Benzinga
Thu, 29 Oct 2026
Supernus Pharmaceuticals Reports Q3 2026 Earnings: EPS of $0.35 and Revenue of $226.8 Million Exceed Estimates - GuruFocus
Thu, 29 Oct 2026
Supernus: Q3 Earnings Snapshot - 10TV
Thu, 29 Oct 2026
Supernus Pharmaceuticals (NASDAQ:SUPN) delivers impressive Q3 2026, full-year sales guidance is optimistic - TradingView
Thu, 29 Oct 2026
Four treatments brought in $192.2 million for Supernus, up 29%. - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 58 (M) |
| Shares Float | 52 (M) |
| Held by Insiders | 4.3 (%) |
| Held by Institutions | 106 (%) |
| Shares Short | 4,990 (K) |
| Shares Short P.Month | 4,670 (K) |
| EPS | -1.92 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 17.72 |
| Profit Margin | -13.3 % |
| Operating Margin | -2.5 % |
| Return on Assets (ttm) | 0.3 % |
| Return on Equity (ttm) | -10.5 % |
| Qtrly Rev. Growth | 32.4 % |
| Gross Profit (p.s.) | 10.39 |
| Sales Per Share | 14.26 |
| EBITDA (p.s.) | 1.89 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 20 (M) |
| Levered Free Cash Flow | 85 (M) |
| PE Ratio | -21.8 |
| PEG Ratio | 0 |
| Price to Book value | 2.35 |
| Price to Sales | 2.93 |
| Price to Cash Flow | 122.34 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|